Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant toripalimab alone or with GP chemotherapy for resectable locally advanced oral squamous cell carcinoma
ChiCTR2300070989Phase 2Not yet recruiting
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab in Oral Mucosal Carcinoma (2 arms), sponsored by Peking University Shenzhen Hospital. Primary endpoints: major pathological response, pathological complete response and 1 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2300070989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070989.